Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LV3-siNlrp3
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
LV3-siNlrp3 is a preclinical research tool designed to investigate the role of the NLRP3 inflammasome in the gut-liver-brain axis, particularly in the context of Parkinson's disease. It consists of a small interfering RNA (siRNA) sequence targeting the Nlrp3 gene, packaged within a lentiviral vector (LV3). In animal models, systemic administration via tail vein injection allows for the knockdown of NLRP3 expression in the liver. This intervention has been shown to reduce peripheral inflammation, suppress the production of pro-inflammatory cytokines, and subsequently mitigate neuroinflammation and dopaminergic neuron loss in the brain. It is primarily used in academic research to explore how peripheral immune responses contribute to neurodegenerative processes.
- Other names
- siNlrp3-lentivirussiNlrp-3-lentivirussiNlrp 3-lentiviruslentiviral-siNlrp3lentiviral-siNlrp-3lentiviral-siNlrp 3
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on LV3-siNlrp3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LV3-siNlrp3.